Stay updated with breaking news from Binding Affinity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers discover the BA.2.86 Omicron lineage with higher transmission potential than current dominant strains, yet show that existing antivirals remain effective. Despite its higher infectivity, BA.2.86 exhibits lower pathogenicity in hamsters, indicating decreased replication capacity may lead to less severe infections.
Researchers at Nagoya University in Japan created and improved artificial intelligence (AI) designs to synthesize a candidate compound for a new gastric acid inhibitor with a better binding affinity than existing drugs.
Researchers examined the antigenicity of the emerging SARS-CoV-2 subvariant BA.2.86, finding that it is not resistant to neutralizing antibodies from previously infected or vaccinated individuals, although it does show increased binding affinity to the ACE-2 receptor. The study highlights the subvariant's sensitivity and resistance to different classes of monoclonal antibodies, offering insights for future treatment and vaccine development.
Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the acquisition of BioPharmics LLC.
A hybrid approach involving a combination of conventional discovery and antibody repurposing to combat COVID-19.